NZ602279A - The use of amisulpride as an anti-emetic - Google Patents

The use of amisulpride as an anti-emetic

Info

Publication number
NZ602279A
NZ602279A NZ602279A NZ60227911A NZ602279A NZ 602279 A NZ602279 A NZ 602279A NZ 602279 A NZ602279 A NZ 602279A NZ 60227911 A NZ60227911 A NZ 60227911A NZ 602279 A NZ602279 A NZ 602279A
Authority
NZ
New Zealand
Prior art keywords
amisulpride
vomiting
induced
nausea
opiate
Prior art date
Application number
NZ602279A
Other languages
English (en)
Inventor
Gabriel Fox
Robert William Gristwood
Nicola Cooper
Julian Clive Gilbert
Original Assignee
Acacia Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42136792&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ602279(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acacia Pharma Ltd filed Critical Acacia Pharma Ltd
Publication of NZ602279A publication Critical patent/NZ602279A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NZ602279A 2010-03-11 2011-03-10 The use of amisulpride as an anti-emetic NZ602279A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1004020.2A GB201004020D0 (en) 2010-03-11 2010-03-11 New therapeutic use
PCT/GB2011/050472 WO2011110854A2 (en) 2010-03-11 2011-03-10 The use of amisulpride as an anti-emetic

Publications (1)

Publication Number Publication Date
NZ602279A true NZ602279A (en) 2014-08-29

Family

ID=42136792

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ602279A NZ602279A (en) 2010-03-11 2011-03-10 The use of amisulpride as an anti-emetic

Country Status (26)

Country Link
US (12) US8686019B2 (enExample)
EP (3) EP2544657B1 (enExample)
JP (2) JP5886213B2 (enExample)
KR (1) KR101738201B1 (enExample)
CN (1) CN102892407B (enExample)
AU (1) AU2011225898B2 (enExample)
BR (1) BR112012022746B1 (enExample)
CA (1) CA2792392C (enExample)
CY (3) CY1115487T1 (enExample)
DK (3) DK2544657T3 (enExample)
EA (1) EA030335B1 (enExample)
ES (3) ES2665418T3 (enExample)
GB (1) GB201004020D0 (enExample)
HR (3) HRP20140744T1 (enExample)
HU (1) HUE037088T2 (enExample)
IL (1) IL221746A (enExample)
LT (1) LT2796171T (enExample)
MX (3) MX2012010411A (enExample)
NO (1) NO2796171T3 (enExample)
NZ (1) NZ602279A (enExample)
PL (3) PL2567690T3 (enExample)
PT (3) PT2567690E (enExample)
RS (3) RS53466B (enExample)
SI (3) SI2544657T1 (enExample)
SM (3) SMT201800188T1 (enExample)
WO (1) WO2011110854A2 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201004020D0 (en) 2010-03-11 2010-04-21 Acacia Pharma Ltd New therapeutic use
CN104435861A (zh) * 2014-12-22 2015-03-25 济南伟传信息技术有限公司 一种治疗妊娠剧吐的茶
GB201506116D0 (en) 2015-04-10 2015-05-27 Acacia Pharma Ltd Kit and combination therapy for nausea and vomiting
EP3344962A4 (en) 2015-09-02 2019-03-13 California Institute of Technology METHOD AND DEVICE FOR THE SPECTROSCOPIC DETECTION OF LOW CONCENTRATIONS OF SULFUR HYDROGEN GAS
GB201618425D0 (en) * 2016-11-01 2016-12-14 Acacia Pharma Ltd method
GB201702250D0 (en) * 2017-02-10 2017-03-29 Acacia Pharma Ltd Method
CN112236138B (zh) 2017-12-05 2024-05-31 赛诺维信制药公司 晶体形式及其制备方法
AU2018379992B2 (en) 2017-12-05 2022-07-21 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
WO2020247603A1 (en) * 2019-06-04 2020-12-10 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
CA3142355A1 (en) 2019-06-04 2020-12-10 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
MX2022001374A (es) * 2019-07-31 2022-03-17 Astellas Pharma Inc Composicion farmaceutica para administracion otica.
BR112023000167A2 (pt) * 2020-07-06 2023-01-31 Acacia Pharma Ltd Terapia de náusea e vômito pós-operatórios
JP2025510741A (ja) 2022-03-21 2025-04-15 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環式ｇｌｐ－１アゴニスト
US20250250269A1 (en) 2022-04-14 2025-08-07 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
CN121002014A (zh) 2022-12-15 2025-11-21 加舒布鲁姆生物公司 具有glp-1激动剂活性的化合物的盐和固体形式
JP2026501285A (ja) 2022-12-22 2026-01-14 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環式ｇｌｐ－１アゴニスト
EP4638455A1 (en) 2022-12-22 2025-10-29 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
KR20250168210A (ko) 2023-02-16 2025-12-02 가셔브룸 바이오, 인크. 헤테로시클릭 glp-1 효능제
US20250019389A1 (en) 2023-06-30 2025-01-16 Gasherbrum Bio, Inc. Heterocyclic agonists
JP2026526054A (ja) 2023-07-13 2026-08-04 アコンカグア・バイオ・インコーポレイテッド 化合物、組成物、および方法
EP4743174A1 (en) 2023-07-13 2026-05-20 Aconcagua Bio, Inc. CALCITONIN AND/OR AMYLIN RECEPTOR ACTIVITY MODULATORS
EP4771001A1 (en) 2023-08-31 2026-07-08 Gasherbrum Bio, Inc. Heteroaryl-heterocycloalkyl-based glp-1 agonists
WO2025137307A1 (en) 2023-12-20 2025-06-26 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2025171341A2 (en) 2024-02-08 2025-08-14 Aconcagua Bio, Inc. Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity
WO2025171340A1 (en) 2024-02-08 2025-08-14 Aconcagua Bio, Inc. The treatment of calcitonin- and/or amylin-receptor associated conditions
TW202600132A (zh) 2024-03-08 2026-01-01 美商安尼波那生物公司 用於治療肥胖症及提高減重之方法
WO2026041075A1 (en) 2024-08-21 2026-02-26 Gasherbrum Bio, Inc. Gpl-1 agonists
WO2026051998A1 (en) 2024-09-04 2026-03-12 Aconcagua Bio, Inc. Compounds, compositions, and methods
WO2026096926A1 (en) 2024-11-01 2026-05-07 Aconcagua Bio, Inc. Compounds, compositions, and methods
WO2026156091A1 (en) 2025-01-15 2026-07-23 Aconcagua Bio, Inc. Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2415099A1 (fr) * 1978-01-20 1979-08-17 Ile De France Nouveaux derives de 4-amino-5-alkylsulfonyl ortho-anisamides, leurs procedes de preparation et leur application comme psychotropes
US6169094B1 (en) * 1998-07-14 2001-01-02 Sanofi-Synthelabo Compositions of (S) (-)-amisulpride
DE10163421A1 (de) 2001-12-21 2003-07-31 Gruenenthal Gmbh Verwendung von (+)-(1S,2S)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol als Antiemetikum
DE102005013726A1 (de) * 2005-03-22 2006-09-28 Grünenthal GmbH Transdermale therapeutische Systeme mit verbesserter Verträglichkeit
GB0506800D0 (en) * 2005-04-04 2005-05-11 Merck Sharp & Dohme New uses
US8551986B2 (en) * 2005-12-08 2013-10-08 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
JP5433236B2 (ja) 2006-01-27 2014-03-05 アプタリス ファーマテック，インコーポレイテッド 弱塩基性選択性セロトニン５−ｈｔ３遮断剤および有機酸を含む薬物送達系
WO2007096489A1 (fr) * 2006-02-17 2007-08-30 Trimaran Limited Nouvelles compositions pharmaceutiques destinees a optimiser des traitements de substitution et elargir la pharmacopee au traitement global des addictions
US7825156B2 (en) * 2007-02-02 2010-11-02 Copharms Method of treating bipolar depression with a benzamide derivative
EP2240022B1 (en) * 2008-01-09 2016-12-28 Charleston Laboratories, Inc. Bilayered tablets comprising oxycodone and promethazine
WO2009126931A2 (en) * 2008-04-11 2009-10-15 Xvasive, Inc. Combination therapy for bipolar disorder
GB201004020D0 (en) 2010-03-11 2010-04-21 Acacia Pharma Ltd New therapeutic use

Also Published As

Publication number Publication date
MX2012010411A (es) 2012-11-30
JP6279526B2 (ja) 2018-02-14
RS53466B (sr) 2014-12-31
US9889118B2 (en) 2018-02-13
EP2544657A2 (en) 2013-01-16
US10525033B2 (en) 2020-01-07
SI2544657T1 (sl) 2014-12-31
CN102892407A (zh) 2013-01-23
US9545426B2 (en) 2017-01-17
US20130022688A1 (en) 2013-01-24
SMT201400127B (it) 2015-05-05
HRP20140744T1 (hr) 2014-09-26
EA030335B1 (ru) 2018-07-31
ES2496092T3 (es) 2014-09-18
DK2796171T3 (en) 2018-05-07
CN102892407B (zh) 2016-03-23
BR112012022746A2 (pt) 2016-07-05
US20130022689A1 (en) 2013-01-24
SI2567690T1 (sl) 2014-12-31
PL2544657T3 (pl) 2014-10-31
EP2544657B1 (en) 2014-07-16
CY1115487T1 (el) 2017-01-04
AU2011225898A1 (en) 2012-10-04
US20200093792A1 (en) 2020-03-26
AU2011225898B2 (en) 2014-07-03
ES2496099T3 (es) 2014-09-18
EP2796171B1 (en) 2018-01-31
PL2567690T3 (pl) 2014-11-28
CA2792392C (en) 2018-06-19
MX388787B (es) 2025-03-20
PT2567690E (pt) 2014-09-03
US20170087128A1 (en) 2017-03-30
US20250186394A1 (en) 2025-06-12
EA201290833A1 (ru) 2013-09-30
SMT201800188T1 (it) 2018-07-17
JP2016028090A (ja) 2016-02-25
RS57032B1 (sr) 2018-05-31
US20210228543A1 (en) 2021-07-29
BR112012022746B1 (pt) 2021-09-28
JP2013522181A (ja) 2013-06-13
SMT201400126B (it) 2015-05-05
US20180042896A1 (en) 2018-02-15
KR101738201B1 (ko) 2017-05-19
US20220296570A1 (en) 2022-09-22
RS53467B (sr) 2014-12-31
US9084765B2 (en) 2015-07-21
DK2567690T3 (da) 2014-08-11
EP2567690B1 (en) 2014-07-16
GB201004020D0 (en) 2010-04-21
US12194022B2 (en) 2025-01-14
US8686019B2 (en) 2014-04-01
MX370629B (es) 2019-12-18
CY1115485T1 (el) 2017-01-04
DK2544657T3 (da) 2014-08-11
CY1120170T1 (el) 2018-12-12
SI2796171T1 (en) 2018-05-31
CA2792392A1 (en) 2011-09-15
US20180353473A1 (en) 2018-12-13
WO2011110854A2 (en) 2011-09-15
MX2019015396A (es) 2020-02-07
ES2665418T3 (es) 2018-04-25
US10085970B2 (en) 2018-10-02
EP2567690A1 (en) 2013-03-13
HUE037088T2 (hu) 2018-08-28
EP2796171A1 (en) 2014-10-29
HRP20180436T1 (hr) 2018-05-04
NO2796171T3 (enExample) 2018-06-30
US20230144973A1 (en) 2023-05-11
KR20130045241A (ko) 2013-05-03
US20150335616A1 (en) 2015-11-26
US9119836B2 (en) 2015-09-01
PT2544657E (pt) 2014-09-03
HK1179152A1 (zh) 2013-09-27
IL221746A (en) 2017-03-30
HRP20140745T1 (hr) 2014-09-26
PT2796171T (pt) 2018-04-24
JP5886213B2 (ja) 2016-03-16
LT2796171T (lt) 2018-05-10
US20140147517A1 (en) 2014-05-29
PL2796171T3 (pl) 2018-07-31
WO2011110854A3 (en) 2011-11-10

Similar Documents

Publication Publication Date Title
MX370629B (es) El uso de amisulpride como un anti-emetico.
GB201111485D0 (en) Drug composition and its use in therapy
JP2016028090A5 (enExample)
NZ625440A (en) Anti-cxcr1 compositions and methods
EA201690107A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
MX2010010026A (es) Agente para tratar enfermedad.
PH12012501772A1 (en) N-(imidazopyrimidin-7-yl)-heteroarylamide derivatives and their use as pde10a inhibitors
MX2011010835A (es) Composicion farmaceutica sublingual que comprende un aceite neutral.
WO2009029958A3 (en) Implantable delivery device
MX2011013201A (es) Composiciones para tratar adiccion a drogas y para mejorar comportamiento relacionado a la adiccion.
NZ616806A (en) Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor
MX347101B (es) Forma de dosis de disolucion rapida de vacuna oral que usa almidon.
EP4650370A3 (en) Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient
MX2019009841A (es) Compuestos y metodos para el tratamiento de la colangitis biliar primaria.
NZ601559A (en) Platelet-derived growth factor compositions and methods for the treatment of tendinopathies
UA109781C2 (uk) Сигма-ліганди для потенціювання аналгетичного ефекту опіоїдів і опіатів при післяопераційному болю і для послаблення залежності від них
MX2016003754A (es) Una composicion farmaceutica estable que contiene amlodipina y valsartan.
WO2015056094A3 (en) Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent
HK1220443A1 (zh) 用作止痛药的全氢喹喔啉衍生物
MX2021004883A (es) Metodos y composiciones para tratar apnea del sue?o.
ZA201905212B (en) Rescue treatment of post operative nausea and vomiting
WO2014093818A3 (en) Use of a novel subcutaneous needle-free technique to deliver testosterone in hypogonadal men
TR201803744T4 (tr) Skleroderma tedavisinde kullanım için naltrekson içeren bileşimler.
MY164112A (en) A combination composition comprising ibuprofen and paracetamol
MX2012007393A (es) Composicion farmaceutica de disolucion rapida comprendiendo lornoxicam.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 MAR 2016 BY PAVIS EG

Effective date: 20150224

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 MAR 2017 BY PAVIS EG

Effective date: 20160301

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 MAR 2018 BY DR. STEFFEN SCHWARZ IPRIS AG

Effective date: 20170227

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 MAR 2019 BY DR. STEFFEN SCHWARZ IPRIS AG

Effective date: 20180303

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 MAR 2020 BY DR. STEFFEN SCHWARZ IPRIS AG

Effective date: 20190228

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 MAR 2021 BY DR. STEFFEN SCHWARZ

Effective date: 20200229

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 MAR 2022 BY ENVOY

Effective date: 20210310

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 MAR 2023 BY ENVOY

Effective date: 20220303

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 MAR 2024 BY CPA GLOBAL

Effective date: 20230309

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 MAR 2025 BY COMPUTER PACKAGES INC

Effective date: 20240217

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 MAR 2026 BY COMPUTER PACKAGES INC

Effective date: 20250217

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 MAR 2027 BY COMPUTER PACKAGES INC

Effective date: 20260301